Vuong Trieu insider trades: Oncotelic Therapeutics (OTLC) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Vuong reports to the SEC
Open-market buys and sales
21 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | OTLC | ↑ Buy | 1,356,990 | $0.02 | $24K | Direct | Oct 30, 2026 (1d) |
| Jun 24, 2026 | OTLC | ↑ Buy | 255,000 | $0.04 | $11K | Direct | Jun 24, 2026 (0d) |
| Jun 17, 2026 | OTLC | ↑ Buy | 335,759 | $0.04 | $15K | Direct | Jun 17, 2026 (0d) |
| Jul 10, 2025 | OTLC | ↑ Buy | 198,737 | $0.01 | $994 | Direct | Jul 10, 2025 (0d) |
| Jan 31, 2025 | OTLC | ↑ Buy | 346,844 | $0.03 | $10K | Direct | Jan 31, 2025 (0d) |
| Nov 22, 2024 | OTLC | ↑ Buy | 298,499 | $0.03 | $9K | Direct | Nov 26, 2024 (4d) |
| Aug 23, 2024 | OTLC | ↑ Buy | 500,000 | $0.02 | $10K | Direct | Aug 27, 2024 (4d) |
| Jun 29, 2023 | OTLC | ↑ Buy | 500,000 | $0.02 | $11K | Direct | Jun 30, 2023 (1d) |
| Jun 16, 2023 | OTLC | ↑ Buy | 100,000 | $0.03 | $3K | Direct | Jun 20, 2023 (4d) |
| Jun 14, 2023 | OTLC | ↑ Buy | 400,000 | $0.03 | $13K | Direct | Jun 16, 2023 (2d) |
| May 26, 2023 | OTLC | ↑ Buy | 126,888 | $0.03 | $4K | Direct | May 31, 2023 (5d) |
| May 2, 2023 | OTLC | ↑ Buy | 100,000 | $0.04 | $5K | Direct | May 2, 2023 (0d) |
| Dec 6, 2022 | OTLC | ↑ Buy | 120,000 | $0.05 | $6K | Direct | Dec 7, 2022 (1d) |
| Nov 22, 2022 | OTLC | ↑ Buy | 70,000 | $0.08 | $6K | Direct | Nov 25, 2022 (3d) |
| Sep 26, 2022 | OTLC | ↑ Buy | 20,000 | $0.07 | $1K | Direct | Sep 28, 2022 (2d) |
| Aug 25, 2022 | OTLC | ↑ Buy | 80,000 | $0.08 | $7K | Direct | Aug 29, 2022 (4d) |
| Nov 19, 2020 | MATN | ↑ Buy | 50,500 | $0.19 | $10K | Direct | Nov 23, 2020 (4d) |
| Mar 26, 2020 | MATN | ↑ Buy | 3,000 | $0.12 | $360 | Direct | Mar 27, 2020 (1d) |
| Jun 9, 2017 | MRNA | ↑ Buy | 10,000 | $0.39 | $4K | Direct | Jun 12, 2017 (3d) |
| Jun 8, 2017 | MRNA | ↑ Buy | 22,500 | $0.39 | $9K | Direct | Jun 8, 2017 (0d) |
| Feb 6, 2017 | MRNA | ↑ Buy | 862,068 | $0.29 | $250K | Indirect | Feb 8, 2017 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other OTLC insiders
Open-market trades in the last 12 months
About Vuong Trieu's insider trades
Vuong Trieu is Chairman and CEO at Oncotelic Therapeutics (OTLC). Since Feb 6, 2017, Vuong has reported 21 open-market purchases worth $407K and no sales on SEC Form 4. In the last 12 months: 3 buys ($50K).
Their filings also include grants and awards (11 filings), conversions (2 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OTLC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.